Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

6.380 -0.060 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher ↗
U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P... 
Via Benzinga
Topics Economy Stocks
News headline image
A Stock Split Catalyst Looms for Chipotle (CMG) Stock on June 6 ↗
Chipotle stock is rising on Wednesday as investors in CMG shares react to the company seeking approval for a 50-for-one split. 
Via InvestorPlace
News headline image
INTC Stock Alert: Intel Just Got a Major $8.5 Billion Boost ↗
Intel stock is rising on Wednesday as investors in INTC shares react to the semiconductor company securing $8.5 billion in funding. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today? ↗
Aquestive Therapeutics stock is falling on Wednesday after the company price a public offering for AQST shares this morning. 
Via InvestorPlace
News headline image
A Preview Of Aquestive Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Where Aquestive Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Preview: Aquestive Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning! 
Via InvestorPlace
News headline image
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
Via Benzinga
News headline image
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. 
Via Benzinga
News headline image
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗
AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 5, 2024 ↗
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
News headline image
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Completes $45 Million Debt Refinancing
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.